hPGDS-IN-1

Modify Date: 2025-08-25 12:01:06

hPGDS-IN-1 structure	Common Name	hPGDS-IN-1
	CAS Number	1234708-04-3	Molecular Weight	416.43300
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₂H₂₀N₆O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of hPGDS-IN-1

hPGDS-IN-1 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay.IC50 value: 12 nMTarget: hPGDSThe detailed information please refer to WO2011044307A1 and WO2010080563A2

Name	2-(pyridin-2-yl)pyrimidine-5-carboxylic acid 3-[5-(1-hydroxy-1-methylethyl)-1,2,4]oxadiazol-3-yl-benzylamide
Synonym	More Synonyms

Description	hPGDS-IN-1 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay.IC50 value: 12 nMTarget: hPGDSThe detailed information please refer to WO2011044307A1 and WO2010080563A2
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> PGE synthase Research Areas >> Inflammation/Immunology
References	[1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414. [2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715. [3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 19

Description

Related Catalog

Signaling Pathways >> Immunology/Inflammation >> PGE synthase

Research Areas >> Inflammation/Immunology

References

[1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.

[2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.

[3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 19

Molecular Formula	C₂₂H₂₀N₆O₃
Molecular Weight	416.43300
Exact Mass	416.16000
PSA	126.92000
LogP	3.13690
Storage condition	2-8℃

2-pyridin-2-yl-pyrimidine-5-carboxylic acid 3-[5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl]benzylamide

SAR-191801

hPGDS-IN-1

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

hPGDS-IN-1

Use of hPGDS-IN-1

Names

hPGDS-IN-1 Biological Activity

Chemical & Physical Properties

Synonyms

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.